A Study of NKT2152, a HIF2α Inhibitor, in Patients With Advanced Clear Cell Renal Cell Carcinoma
NiKang Therapeutics, Inc.
NiKang Therapeutics, Inc.
Ankara University
University Hospital of North Norway
Maastricht Radiation Oncology
Threshold Pharmaceuticals
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Threshold Pharmaceuticals
Siemens Molecular Imaging
Novacea